Novartis(US:NVS) Xin Lang Cai Jing·2025-09-03 13:23Core Insights - A new strategic collaboration agreement has been established between 舶望制药 and 诺华 to jointly develop multiple cardiovascular products, building on their existing partnership initiated in January 2024 [1] Group 1: Collaboration Details - The new agreement includes licensing and preferential rights, where 舶望制药 grants 诺华 options for two early-stage molecules outside of China for treating severe hypertriglyceridemia (sHTG) and mixed dyslipidemia, along with preferential negotiation rights for the BW-00112 (ANGPTL3) product, which is currently in Phase II clinical trials in the US and China [1] - For another siRNA candidate drug in preclinical research, 舶望制药 grants 诺华 exclusive licensing rights outside of China, including a reciprocal profit and loss sharing option in the US and China, with Phase I clinical trials expected to start in 2026 [2] Group 2: Financial Aspects - 舶望制药 will receive an upfront payment of $160 million, with potential milestone and option payments, as well as tiered royalties from commercial sales, with total potential milestone value reaching $5.2 billion [3] - 诺华 has expressed preliminary interest in participating in 舶望制药's next round of equity financing, with specific participation details (including investment amount and timing) subject to due diligence and formal agreement [3]